title: Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway.
abstract: Basic fibroblast growth factor (bFGF) is a multifunctional growth factor in glioma cells and has been proved to be associated with the grade malignancy of glioma and prognosis of patients. Although there is evidence showing that bFGF plays an important role in proliferation, differentiation, angiogenesis, and survival of glioma cells, the effect of bFGF on chemosensitivity of glioma has not been verified. In this study, we analyzed the relationship between bFGF and chemotherapy resistance, with the objective of offering new strategy for chemotherapy of glioma patients. Here, siRNA was used to silence the expression of bFGF in glioma cell lines including U87 and U251 followed by chemotherapy of temozolomide (TMZ). Then, the characters of glioma including proliferation, apoptosis, migration, and cell cycle were studied in U87 and U251 cell lines. Our results demonstrated that silencing bFGF enhanced the effect of TMZ by inhibiting proliferation and migration, blocking cell cycle in G0/G1, and promoting apoptosis. In addition, the phosphorylation level of MAPK was measured to explore the mechanism of chemosensitization. The results showed that bFGF could promote the activation of the MAPK signal pathway. Our data indicated that bFGF might be a potential target for chemotherapy through the MAPK signal pathway.
authors.affiliation: Tianjin Cerebral Vascular and Neural Degenerative Disease Key Laboratory, Tianjin Neurosurgery Institute, Tianjin Huanhu Hospital, Tianjin 300060, China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Wang
authors.affiliation: The Graduate School, Tianjin Medical University, Tianjin 300070, China.
authors.forename: Jixiang
authors.initials: J
authors.lastname: Du
authors.affiliation: The Graduate School, Tianjin Medical University, Tianjin 300070, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
authors.affiliation: Tianjin Cerebral Vascular and Neural Degenerative Disease Key Laboratory, Tianjin Neurosurgery Institute, Tianjin Huanhu Hospital, Tianjin 300060, China.
authors.forename: Lixia
authors.initials: L
authors.lastname: Xu
authors.affiliation: The Graduate School, Tianjin Medical University, Tianjin 300070, China.
authors.forename: Xiuyu
authors.initials: X
authors.lastname: Wang
authors.affiliation: Tianjin Cerebral Vascular and Neural Degenerative Disease Key Laboratory, Tianjin Neurosurgery Institute, Tianjin Huanhu Hospital, Tianjin 300060, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Liu
authors.affiliation: Tianjin Cerebral Vascular and Neural Degenerative Disease Key Laboratory, Tianjin Neurosurgery Institute, Tianjin Huanhu Hospital, Tianjin 300060, China wangjinhuanfch@126.com.
authors.forename: Jinhuan
authors.initials: J
authors.lastname: Wang
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D059447:Cell Cycle Checkpoints / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects / Q000235:genetics; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000235:genetics; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics; D000077204:Temozolomide; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D018906:Antineoplastic Agents, Alkylating; C494826:BAX protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; D034741:RNA, Small Interfering; D051028:bcl-2-Associated X Protein; D016222:Fibroblast Growth Factor 2; D003606:Dacarbazine; D000077204:Temozolomide
keywords: bFGF; chemosensitivity; combined chemotherapy; drug resistance; gliomas; temozolomide